AstraZeneca (AZN) Denied Request for Preliminary Injunction in Generic Quetiapine/FDA Suit
Tweet
Share
E-mailGet Alerts AZN Hot Sheet
Join SI Premium – FREE
AstraZeneca (NYSE: AZN) reports that on March 23, 2012 the US District Court for the District of Columbia issued an opinion and order in AstraZeneca’s lawsuit against the US Food and Drug Administration (FDA) regarding final marketing approval of generic quetiapine. The Court denied the Company’s request for a preliminary injunction and dismissed the lawsuit without prejudice.
Notwithstanding the Court’s decision, the Company continues to believe strongly in the merits of its position and is evaluating its options.
Notwithstanding the Court’s decision, the Company continues to believe strongly in the merits of its position and is evaluating its options.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small ce
- CoVolt Power files for proposed IPO
- Sigma Lithium resumes full operations after signing TAC agreement
Create E-mail Alert Related Categories
Corporate News, FDA, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
